Jove
Visualize
Contact Us

Related Experiment Videos

Enfuvirtide (Fuzeon)

    Project Inform Perspective
    |December 31, 2003
    PubMed
    Summary
    This summary is machine-generated.

    Enfuvirtide (Fuzeon) is a novel entry inhibitor approved for HIV treatment in children and adults with prior therapy. It blocks HIV entry into immune cells by preventing fusion with the cell wall.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Everything antiretroviral: 5th IAS conference, Cape Town, South Africa.

    Project Inform perspective·2012
    Same journal

    Well implemented, President Obama's national HIV/AIDS strategy is precisely what is needed to further control HIV/AIDS.

    Project Inform perspective·2011
    Same journal

    Finding health care; preparing for the future.

    Project Inform perspective·2011
    Same journal

    Protecting people with HIV in the California budget.

    Project Inform perspective·2010
    Same journal

    Current drugs in clinical study.

    Project Inform perspective·2010
    Same journal

    HIV treatment information.

    Project Inform perspective·2010
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Virology
    • Immunology
    • Pharmacology

    Background:

    • Human Immunodeficiency Virus (HIV) infection remains a significant global health challenge.
    • Antiretroviral therapy has evolved, necessitating new drug classes to combat resistance and improve outcomes.
    • Enfuvirtide (Fuzeon) represents a new class of antiretroviral agents known as entry inhibitors.

    Discussion:

    • Enfuvirtide functions by inhibiting the fusion of the HIV virus with the host immune cell membrane.
    • This mechanism of action occurs early in the HIV replication cycle, prior to viral genetic material entering the cell.
    • The drug's approval in 2003 marked a significant advancement in HIV treatment options, particularly for treatment-experienced patients.

    Key Insights:

    • Enfuvirtide's unique mechanism targets the initial stage of HIV cellular infection.

    Related Experiment Videos

  • It offers a therapeutic option for individuals with multi-drug resistant HIV strains.
  • The drug's efficacy is demonstrated in combination with other antiretroviral agents.

    • Outlook:

    • Further research into entry inhibitors may lead to more effective HIV prevention and treatment strategies.
    • Understanding viral fusion mechanisms is crucial for developing next-generation antiretrovirals.
    • Continued development of novel drug classes is essential to overcome HIV drug resistance.